Genmab A/S (GMAB.CO)

DKK 1486.5

(4.13%)

Total Debt Summary of Genmab A/S

  • Genmab A/S's latest annual total debt in 2023 was 770 Million DKK , up 28.98% from previous year.
  • Genmab A/S's latest quarterly total debt in 2024 Q2 was 1.01 Billion DKK , up 0.89% from previous quarter.
  • Genmab A/S reported annual total debt of 597 Million DKK in 2022, up 40.47% from previous year.
  • Genmab A/S reported annual total debt of 425 Million DKK in 2021, up 33.23% from previous year.
  • Genmab A/S reported quarterly total debt of 1.01 Billion DKK for 2024 Q2, up 0.89% from previous quarter.
  • Genmab A/S reported quarterly total debt of 829 Million DKK for 2023 Q1, up 38.86% from previous quarter.

Annual Total Debt Chart of Genmab A/S (2023 - 2002)

Historical Annual Total Debt of Genmab A/S (2023 - 2002)

Year Total Debt Total Debt Growth
2023 770 Million DKK 28.98%
2022 597 Million DKK 40.47%
2021 425 Million DKK 33.23%
2020 319 Million DKK 76.24%
2019 181 Million DKK 0.0%
2018 - DKK 0.0%
2017 - DKK 0.0%
2016 - DKK -100.0%
2015 118 Thousand DKK -66.76%
2014 355 Thousand DKK -85.71%
2013 2.48 Million DKK -56.1%
2012 5.66 Million DKK -52.22%
2011 11.84 Million DKK -91.14%
2010 133.71 Million DKK 436.11%
2009 24.94 Million DKK 69.69%
2008 14.69 Million DKK -6.18%
2007 15.66 Million DKK -13.95%
2006 18.2 Million DKK -20.97%
2005 23.03 Million DKK -20.58%
2004 29 Million DKK 20.16%
2003 24.13 Million DKK 75.22%
2002 13.77 Million DKK 0.0%

Peer Total Debt Comparison of Genmab A/S

Name Total Debt Total Debt Difference
ALK-Abelló A/S 765 Million DKK -0.654%
Bavarian Nordic A/S 145.3 Million DKK -429.931%
Gubra A/S 71.43 Million DKK -977.903%
Novo Nordisk A/S 27 Billion DKK 97.149%
Orphazyme A/S - DKK -Infinity%
Pharma Equity Group A/S 30.22 Million DKK -2447.897%
Zealand Pharma A/S 200.27 Million DKK -284.471%